Effectiveness of N-N-bis-P-chlorophenyl-3p-tolyl glutaric acid diamide (SRC-3605) as a hypocholesterolaemic compound in hypercholesterolaemic female weanling and adult rats.
SRC-3605, N-N-bis-P-chlorophenyl 3-p-tolyl glutaric acid diamide, was studied for its hypocholesterolaemic effect on serum and liver cholesterol in hypercholesterolaemic weanling and adult female rats. Weanlings were administered doses of SRC-3605 ranging from 100 to 300 mg/kg body weight for 4 or 8 consecutive days. The greatest hypocholesterolaemic effect was observed with doses of 150, 200 and 250 mg, although a progressive decreases in serum cholesterol was noted with increasing doses. Hepatic cholesterol decreases supported the serum data, but were inconsistent. Hypercholesterolaemic adult animals received 50, 100, 150 or 200 mg/kg body weight of either SRC-3605 or clofibrinic acid for 4 days. A decrease in serum cholesterol levels was observed only with the 200 mg SRC-3605. No clear-cut influence of the either compounds was found on hepatic cholesterol. The results indicated that SRC-3605 possesses the property to reduce both serum and liver cholesterol in hypocholesterolaemic weanling female rats.
D000818:Animals; D000833:Animals, Suckling; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D002784:Cholesterol / Q000032:analysis* / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use; D005260:Female; D005977:Glutarates / Q000494:pharmacology*; D006937:Hypercholesterolemia / Q000188:drug therapy; D008099:Liver / Q000032:analysis / Q000187:drug effects*; D051381:Rats
D000924:Anticholesteremic Agents; D005977:Glutarates; C018180:N,N-bis(p-chlorophenyl)-3-(p-tolyl)glutaric acid; D002784:Cholesterol; D002994:Clofibrate